• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

什么导致肥厚型心肌病?

What Causes Hypertrophic Cardiomyopathy?

机构信息

Division of Cardiovascular Medicine, Department of Medicine and Harvard Medical School, Boston, Massachusetts.

Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

出版信息

Am J Cardiol. 2022 Sep 15;179:74-82. doi: 10.1016/j.amjcard.2022.06.017. Epub 2022 Jul 14.

DOI:10.1016/j.amjcard.2022.06.017
PMID:35843734
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9818026/
Abstract

Hypertrophic cardiomyopathy (HCM) is a global and relatively common cause of patient morbidity and mortality and is among the first reported monogenic cardiac diseases. For 30 years, the basic etiology of HCM has been attributed largely to variants in individual genes encoding cardiac sarcomere proteins, with the implication that HCM is fundamentally a genetic disease. However, data from clinical and network medicine analyses, as well as contemporary genetic studies show that single gene variants do not fully explain the broad and diverse HCM clinical spectrum. These transformative advances place a new focus on possible novel interactions between acquired disease determinants and genetic context to produce complex HCM phenotypes, also offering a measure of caution against overemphasizing monogenics as the principal cause of this disease. These new perspectives in which HCM is not a uniformly genetic disease but likely explained by multifactorial etiology will also unavoidably impact how HCM is viewed by patients and families in the clinical practicing community going forward, including relevance to genetic counseling and access to healthcare insurance and psychosocial wellness.

摘要

肥厚型心肌病(HCM)是全球范围内较为常见的导致患者发病和死亡的原因之一,也是最早报道的单基因心脏疾病之一。三十年来,HCM 的基本病因主要归因于编码心肌肌节蛋白的个体基因突变,这意味着 HCM 从根本上说是一种遗传性疾病。然而,来自临床和网络医学分析以及当代遗传研究的数据表明,单基因突变并不能完全解释广泛而多样的 HCM 临床表型。这些变革性的进展将新的关注点放在获得性疾病决定因素与遗传背景之间可能存在的新的相互作用上,以产生复杂的 HCM 表型,同时也对过分强调单基因作为该病主要病因的做法提出了一定程度的警示。这些新的观点认为,HCM 不是一种一致的遗传性疾病,而是可能由多因素病因引起,这也将不可避免地影响临床实践社区中的患者和家属对 HCM 的看法,包括对遗传咨询以及获得医疗保健保险和心理健康的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/731e/9818026/daae17655d96/nihms-1853998-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/731e/9818026/cfd9af51984d/nihms-1853998-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/731e/9818026/daae17655d96/nihms-1853998-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/731e/9818026/cfd9af51984d/nihms-1853998-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/731e/9818026/daae17655d96/nihms-1853998-f0002.jpg

相似文献

1
What Causes Hypertrophic Cardiomyopathy?什么导致肥厚型心肌病?
Am J Cardiol. 2022 Sep 15;179:74-82. doi: 10.1016/j.amjcard.2022.06.017. Epub 2022 Jul 14.
2
Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy.低外显率肌节变异对肥厚型心肌病的累积风险有影响。
Circulation. 2025 Mar 18;151(11):783-798. doi: 10.1161/CIRCULATIONAHA.124.069398. Epub 2024 Dec 5.
3
Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives.肥厚型心肌病 20 年后的遗传学:临床观点。
J Am Coll Cardiol. 2012 Aug 21;60(8):705-15. doi: 10.1016/j.jacc.2012.02.068. Epub 2012 Jul 11.
4
Differential contributions of sarcomere and mitochondria-related multigene variants to the endophenotype of hypertrophic cardiomyopathy.肌节和线粒体相关多基因变异对肥厚型心肌病表型的差异贡献。
Mitochondrion. 2020 Jul;53:48-56. doi: 10.1016/j.mito.2020.04.010. Epub 2020 May 4.
5
Pathogenic Mechanisms of Hypertrophic Cardiomyopathy beyond Sarcomere Dysfunction.肥厚型心肌病的致病机制远不止于肌节功能障碍。
Int J Mol Sci. 2021 Aug 19;22(16):8933. doi: 10.3390/ijms22168933.
6
Sarcomere mutation negative hypertrophic cardiomyopathy is associated with ageing and obesity.肌节突变阴性肥厚型心肌病与衰老和肥胖有关。
Open Heart. 2021 Feb;8(1). doi: 10.1136/openhrt-2020-001560.
7
Molecular Genetic Basis of Hypertrophic Cardiomyopathy.肥厚型心肌病的分子遗传学基础。
Circ Res. 2021 May 14;128(10):1533-1553. doi: 10.1161/CIRCRESAHA.121.318346. Epub 2021 May 13.
8
Hypertrophic Cardiomyopathy: Diverse Pathophysiology Revealed by Genetic Research, Toward Future Therapy.肥厚型心肌病:遗传学研究揭示的多种病理生理学机制,迈向未来的治疗方法。
Keio J Med. 2020 Dec 25;69(4):77-87. doi: 10.2302/kjm.2019-0012-OA. Epub 2020 Mar 28.
9
Phenotypic Expression and Outcomes in Individuals With Rare Genetic Variants of Hypertrophic Cardiomyopathy.肥厚型心肌病罕见基因突变个体的表型表达和结局。
J Am Coll Cardiol. 2021 Sep 14;78(11):1097-1110. doi: 10.1016/j.jacc.2021.07.017.
10
Molecular analysis of sarcomeric and non-sarcomeric genes in patients with hypertrophic cardiomyopathy.肥厚型心肌病患者肌节和非肌节基因的分子分析。
Gene. 2016 Feb 15;577(2):227-35. doi: 10.1016/j.gene.2015.11.048. Epub 2015 Dec 2.

引用本文的文献

1
Percutaneous endocardial septal radiofrequency ablation in patients with hypertrophic obstructive cardiomyopathy.肥厚性梗阻性心肌病患者的经皮心内膜间隔射频消融术
BMC Cardiovasc Disord. 2025 Aug 2;25(1):564. doi: 10.1186/s12872-025-05002-1.
2
Tailored therapeutics for cardiomyopathies.针对心肌病的个性化疗法。
Nat Rev Cardiol. 2025 Jun 27. doi: 10.1038/s41569-025-01183-6.
3
Molecular mechanisms and intervention approaches of heart failure (Review).心力衰竭的分子机制及干预方法(综述)

本文引用的文献

1
Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review.肥厚型心肌病的管理:美国心脏病学会的最新综述。
J Am Coll Cardiol. 2022 Feb 1;79(4):390-414. doi: 10.1016/j.jacc.2021.11.021.
2
Impact of comorbidities on atrial fibrillation and sudden cardiac death in hypertrophic cardiomyopathy.合并症对肥厚型心肌病中心律失常和心源性猝死的影响。
J Cardiovasc Electrophysiol. 2022 Jan;33(1):20-29. doi: 10.1111/jce.15304. Epub 2021 Dec 8.
3
Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies.
Int J Mol Med. 2025 Aug;56(2). doi: 10.3892/ijmm.2025.5566. Epub 2025 Jun 13.
4
GADD45A suppression contributes to cardiac remodeling by promoting inflammation, fibrosis and hypertrophy.GADD45A抑制通过促进炎症、纤维化和肥大来促成心脏重塑。
Cell Mol Life Sci. 2025 Apr 30;82(1):189. doi: 10.1007/s00018-025-05704-x.
5
Tale of three services: early UK experience with mavacamten treatment for hypertrophic cardiomyopathy with left ventricular outflow tract obstruction.三项服务的故事:英国早期使用马伐卡坦治疗左心室流出道梗阻性肥厚型心肌病的经验
Open Heart. 2025 Apr 17;12(1):e003218. doi: 10.1136/openhrt-2025-003218.
6
Multimodal ultrasound assessment of myocardial perfusion and contractile function in patients with hypertrophic cardiomyopathy and their first-degree relatives.肥厚型心肌病患者及其一级亲属心肌灌注和收缩功能的多模态超声评估
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 Dec 28;49(12):1934-1940. doi: 10.11817/j.issn.1672-7347.2024.240171.
7
Outcomes of transcatheter aortic valve replacement in patients with hypertrophic cardiomyopathy: a systematic review.肥厚型心肌病患者经导管主动脉瓣置换术的结局:一项系统评价
Ann Transl Med. 2025 Feb 28;13(1):6. doi: 10.21037/atm-24-41. Epub 2025 Feb 25.
8
The Role of Signalling Pathways in Myocardial Fibrosis in Hypertrophic Cardiomyopathy.信号通路在肥厚型心肌病心肌纤维化中的作用
Rev Cardiovasc Med. 2025 Feb 21;26(2):27152. doi: 10.31083/RCM27152. eCollection 2025 Feb.
9
Model-Informed Recommendation of Mavacamten Posology for Chinese Adults With Obstructive Hypertrophic Cardiomyopathy.模型指导下的马伐卡坦对中国成人梗阻性肥厚型心肌病给药方案的推荐
CPT Pharmacometrics Syst Pharmacol. 2025 Apr;14(4):751-758. doi: 10.1002/psp4.13312. Epub 2025 Jan 28.
10
Prevalence, Patient Characteristics, and Treatment of Patients with Hypertrophic Cardiomyopathy: A Nationwide Payer Database Study.肥厚型心肌病患者的患病率、患者特征及治疗:一项全国性医保数据库研究
Cardiol Ther. 2025 Mar;14(1):71-86. doi: 10.1007/s40119-024-00396-z. Epub 2025 Jan 15.
小肥大型心肌病基因,对心肌病遗传学的主要认识。
Nat Rev Cardiol. 2022 Mar;19(3):151-167. doi: 10.1038/s41569-021-00608-2. Epub 2021 Sep 15.
4
Phenotypic Expression and Outcomes in Individuals With Rare Genetic Variants of Hypertrophic Cardiomyopathy.肥厚型心肌病罕见基因突变个体的表型表达和结局。
J Am Coll Cardiol. 2021 Sep 14;78(11):1097-1110. doi: 10.1016/j.jacc.2021.07.017.
5
Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy.小鼠和人类肥厚型心肌病中分子表型的差异。
Sci Rep. 2021 Jun 23;11(1):13163. doi: 10.1038/s41598-021-89451-6.
6
Time to Think Differently About Sarcomere-Negative Hypertrophic Cardiomyopathy.是时候对肌节阴性肥厚型心肌病进行不同的思考了。
Circulation. 2021 Jun 22;143(25):2415-2417. doi: 10.1161/CIRCULATIONAHA.121.053527. Epub 2021 Jun 21.
7
Discordant clinical features of identical hypertrophic cardiomyopathy twins.同卵肥厚型心肌病双胞胎临床表现不一致。
Proc Natl Acad Sci U S A. 2021 Mar 9;118(10). doi: 10.1073/pnas.2021717118.
8
Programmable C:G to G:C genome editing with CRISPR-Cas9-directed base excision repair proteins.利用 CRISPR-Cas9 指导的碱基切除修复蛋白对可编程的 C:G 到 G:C 基因组编辑。
Nat Commun. 2021 Mar 2;12(1):1384. doi: 10.1038/s41467-021-21559-9.
9
Comprehensive characterization of protein-protein interactions perturbed by disease mutations.全面描绘受疾病突变影响的蛋白质-蛋白质相互作用。
Nat Genet. 2021 Mar;53(3):342-353. doi: 10.1038/s41588-020-00774-y. Epub 2021 Feb 8.
10
Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes.基于网络的个体化互作组学在肥厚型心肌病精准医学中的应用及其对其他临床表型的影响。
Nat Commun. 2021 Feb 8;12(1):873. doi: 10.1038/s41467-021-21146-y.